CAS NO: | 861875-60-7 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
2mg | 电议 |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
500mg | 电议 |
生物活性 |
NVP-BAW2881 (BAW2881) is a potent and selectiveVEGFR2inhibitor with anIC50of 4 nM. |
||||||||||||||||
IC50& Target |
|
||||||||||||||||
体外研究 (In Vitro) |
The VEGF-driven cellular receptor autophosphorylation in CHO cells of BAW2881 is inhibited with an IC50of 4 nM. BAW2881 inhibits a limited number of kinases including c-RAF, B-RAF, RET, ABL, and TIE-2 at sub-μM IC50s[1]. NVP-BAW2881 is highly selective for VEGFR, although it also demonstrates activity against Tie2 (IC50=650 nM) and RET (IC50=410 nM). The IC50values of NVP-BAW2881 toward a wide panel of other kinases are >10 μM. NVP-BAW2881 inhibits VEGF-A-induced phosphorylation of VEGFR-2 in HUVECs and in VEGFR-2-transfected Chinese hamster ovary cells, with IC50values of 2.9 and 4.2 nM, respectively[2].
|
||||||||||||||||
体内研究 (In Vivo) |
In a transgenic mouse model of psoriasis, NVP-BAW2881 reduces the number of blood and lymphatic vessels and infiltrating leukocytes in the skin, and normalized the epidermal architecture. NVP-BAW2881 also displays strong anti-inflammatory effects in models of acute inflammation; pretreatment with topical NVP-BAW2881 significantly inhibits VEGF-A-induced vascular permeability in the skin of pigs and mice[2].
|
||||||||||||||||
分子量 |
424.38 |
||||||||||||||||
性状 |
Solid |
||||||||||||||||
Formula |
C22H15F3N4O2 |
||||||||||||||||
CAS 号 |
861875-60-7 |
||||||||||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||
储存方式 |
|
||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : ≥ 33 mg/mL(77.76 mM) *"≥" means soluble, but saturation unknown.
配制储备液
*
请根据半岛bd体育手机客户端 在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的半岛bd体育手机客户端 失效。
In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
*
以上所有助溶剂都可在本网站选购。
|